Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | UBE2N | P61088 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 5/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3359397 | 0.88 | KDM4E (0.53) | KDM4EALDH1A1MAPK1MAOAMAOB | |
| SCHEMBL3363862 | 0.87 | KDM4E (0.51) | KDM4EALDH1A1MAPK1MAOAMAOB | |
| SCHEMBL9132405 | 0.85 | KDM4E (0.50) | KDM4EALDH1A1MAPK1MAOAMAOB | |
| SCHEMBL9133522 | 0.85 | KDM4E (0.50) | KDM4EALDH1A1MAPK1MAOAMAOB | |
| SCHEMBL6996035 | 0.78 | MCL1 (0.45) | KDM4EALDH1A1MAPK1MAOAMAOB | |
| SCHEMBL498438 | 0.76 | KDM4E (0.53) | KDM4EALDH1A1MAPK1MAOAMAOB | |
| SCHEMBL5489202 | 0.76 | KDM4E (0.53) | KDM4EALDH1A1MAPK1MAOAMAOB | |
| SCHEMBL4187788 | 0.76 | KDM4E (0.53) | KDM4EALDH1A1MAPK1MAOAMAOB | |
| SCHEMBL4182898 | 0.76 | KDM4E (0.53) | KDM4EALDH1A1MAPK1MAOAMAOB | |
| SCHEMBL11435078 | 0.76 | L3MBTL1 (0.57) | KDM4EALDH1A1MAPK1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0840781-B1 | METHODS AND DEVICES FOR THE REMOVAL OF PSORALENS FROM BLOOD PRODUCTS | CERUS CORP (US) | 2009-12-09 | — | — | EP | disclosed |
| EP-1776952-A2 | Photodecontamination of pathogens in blood | Cerus Corporation (US) | 2007-04-25 | — | — | EP | disclosed |
| EP-1584622-A2 | Compounds for the photodecontamination of pathogens in blood | Cerus Corporation (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20030185804-A1 | Compounds for the photodecontamination of pathogens in blood | CERUS CORPORATION (US) | 2003-10-02 | — | — | US | disclosed |
| US-20020192632-A1 | Method and devices for the removal of psoralens from blood products | HEI DEREK J (US) | 2002-12-19 | — | — | US | disclosed |
| US-20020115585-A1 | Method and devices for the removal of psoralens from blood products | HEI DEREK J (US) | 2002-08-22 | — | — | US | disclosed |
| US-6218100-B1 | ELIMINATING VIRAL DISEASE TRANSMISSION THROUGH BLOOD PRODUCTS VIA SAID COMPOSITIONS WHICH HAVE ABILITY TO INACTIVATE PATHOGENS IN PRESENCE OF ULTAVIOLET LIGHT WITHOUT EFFECTING BLOOD PRODUCT FUNCTIONING OR EXHIBITING MUTAGENICITY | CERUS CORPORATION | 2001-04-17 | — | — | US | disclosed |
| US-6194139-B1 | USING A PSORALEN COMPOUND | CERUS CORPORATION | 2001-02-27 | — | — | US | disclosed |
| US-6017691-A | MIXTURE WITH IMPROVED VIRICIDAL ACTIVITY AND LOW MUTAGENICITY | CERUS CORPORATION (US) | 2000-01-25 | — | — | US | disclosed |
| US-6004741-A | ENHANCED BINDING TO NUCLEIC ACID OF PATHOGENS, RESULTING IN SAFER, MORE EFFICIENT, AND RELIABLE INACTIVATION OF PATHOGENS IN BLOOD PRODUCTS | CERUS CORPORATION (US) | 1999-12-21 | — | — | US | disclosed |
| US-5871900-A | BACTERIA OR VIRUSES IN BLOOD | CERUS CORPORATION (US) | 1999-02-16 | — | — | US | disclosed |
| US-5712085-A | PLATELET STORAGE | CERUS CORPORATION (US) | 1998-01-27 | — | — | US | disclosed |
| WO-1997021346-A1 | INACTIVATION OF NON-ENVELOPED VIRUS | CERUS CORPORATION (US) | 1997-06-19 | — | — | WO | disclosed |
| US-5625079-A | Synthesizing psoralen compounds useful as intermediates | CERUS CORPORATION (US) | 1997-04-29 | — | — | US | disclosed |
| US-5593823-A | FOR A SUFFICIENT DURATION, INTENSITY AND WAVELENGTH | CERUS CORPORATION (US) | 1997-01-14 | — | — | US | disclosed |
| WO-1996039820-A1 | METHODS OF INACTIVATING LEUKOCYTES AND INHIBITING CYTOKINE PRODUCTION IN BLOOD PRODUCTS | CERUS CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5556993-A | PSORALEN COMPOUNDS FOR DEACTIVATION OF HEPATITIS AND HIVVIRUSES | STERITECH, INC. (US) | 1996-09-17 | — | — | US | disclosed |
| WO-1996014739-A1 | COMPOUNDS FOR THE PHOTODECONTAMINATION OF PATHOGENS IN BLOOD | CERUS CORPORATION (US) | 1996-05-23 | — | — | WO | disclosed |
| EP-0707476-A1 | COMPOUNDS FOR THE PHOTODECONTAMINATION OF PATHOGENS IN BLOOD | STERITECH, INC (US) | 1996-04-24 | — | — | EP | disclosed |
| WO-1995000141-A1 | COMPOUNDS FOR THE PHOTODECONTAMINATION OF PATHOGENS IN BLOOD | STERITECH, INC. (US) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030185804-A1 | Compounds for the photodecontamination of pathogens in blood | HMBS, HLA-C, HLA-B | KDM4E 2849/4885ALDH1A1 680/4885MAPK1 4468/4885 |
| US-20020115585-A1 | Method and devices for the removal of psoralens from blood products | SERPINB10, RAD50, F2 | KDM4E 3546/4885ALDH1A1 2114/4885MAPK1 4212/4885 |
| US-20020192632-A1 | Method and devices for the removal of psoralens from blood products | PLG, SERPINB10, RAD50 | KDM4E 3483/4885ALDH1A1 1951/4885MAPK1 4591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.